metformin + digital lifestyle intervention

Metformin + digital lifestyle intervention is a combined pharmacological and behavioral approach being evaluated by St. Jude Children's Research Hospital to prevent the progression of prediabetes to type 2 diabetes in adult survivors of childhood cancer. This intervention consists of the oral administration of metformin hydrochloride, a biguanide insulin sensitizer, alongside a digital lifestyle change program delivered via the Noom smartphone application. Metformin works primarily by inhibiting mitochondrial complex I and activating AMP-activated protein kinase (AMPK), which leads to reduced hepatic glucose production and improved peripheral insulin sensitivity. The digital component provides a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring. The PREDM pilot study specifically addresses the high metabolic risk faced by childhood cancer survivors, who are twice as likely to develop prediabetes compared to the general population.

Brand names

NoomGlucophage

Other names

metformin-St. Jude Children's Research Hospital-prediabetesMetformin and lifestyle intervention to prevent diabetes in childhood cancer survivors